<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Extraction extraction-result-3890 - Theorizer</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.1/css/all.min.css">
    <link rel="stylesheet" href="../style.css">
</head>
<body>
    <div class="header">
        <a href="../index.html"><i class="fas fa-flask"></i> Theorizer</a>
    </div>

    <div class="content">
        <h1>Extracted Data Details for extraction-result-3890</h1>

        <div class="section">
            <h2>Extracted Data (Header)</h2>
            <div class="info-section">
                <p><strong>Extraction ID:</strong> extraction-result-3890</p>
                <p><strong>Extraction Schema Used (ID):</strong> <a href="../schemas/extraction-schema-94.html">extraction-schema-94</a></p>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed causes or mechanisms of Alzheimer's disease, and any methods or biomarkers used for its detection, including evidence, results, and limitations.</div>
                <p><strong>Paper ID:</strong> paper-267515482</p>
                <p><strong>Paper Title:</strong> <a href="https://apcz.umk.pl/JEHS/article/download/47975/37568/130632" target="_blank">Alzheimer's Disease-A Comprehensive Review</a></p>
                <p><strong>Paper Abstract:</strong> Introduction: Alzheimer's disease (AD) remains a pervasive and challenging neurodegenerative disorder with profound implications for individuals, families, and societies. As the most prevalent cause of dementia globally, AD's prevalence is set to rise significantly in the context of an aging population. This introductory section emphasizes the urgent need for a comprehensive understanding of the disease, encompassing both its molecular intricacies and the socio-economic burden. With age being the primary risk factor, recent research has delved into the complex interplay of genetic predisposition and environmental influences, reshaping our understanding of AD from a multifactorial perspective. Current State of Knowledge:</p>
                <p><strong>Cost:</strong> 0.013</p>
            </div>
        </div>

        <div class="section">
            <h2>Extracted Data (Details)</h2>
            <div class="extraction-instance-container" id="e3890.0">
                <h3 class="extraction-instance">Extracted Data Instance 0 (e3890.0)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed causes or mechanisms of Alzheimer's disease, and any methods or biomarkers used for its detection, including evidence, results, and limitations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Aβ / Amyloid-beta</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Amyloid-beta peptide accumulation / Amyloid cascade hypothesis</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Extracellular aggregation of amyloid-beta peptides into plaques is presented as a central proposed mechanism in AD, thought to disrupt synapses and trigger downstream neurodegeneration and inflammation.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_cause</strong></td>
                            <td>Accumulation and aggregation of amyloid-beta peptides (amyloid plaques) driving synaptic dysfunction and downstream neurodegeneration (the amyloid cascade hypothesis).</td>
                        </tr>
                        <tr>
                            <td><strong>cause_evidence</strong></td>
                            <td>Review cites historical neuropathology showing amyloid plaque cores composed of aggregated Aβ (Masters et al., 1985) and summarizes the amyloid cascade hypothesis (Hardy & Higgins 1992; Selkoe & Hardy 2016). Evidence referenced includes neuropathologic observations in humans and experimental models linking amyloid to synaptic disruption and neuroinflammation; clinical trials targeting Aβ (e.g., aducanumab, solanezumab, bapineuzumab) are noted, with mixed/limited clinical benefit reported in phase 3 trials (Doody et al.; Honig et al.). The paper is a review (no new primary data).</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>Amyloid PET imaging; CSF Aβ measurements</td>
                        </tr>
                        <tr>
                            <td><strong>biomarker_or_finding</strong></td>
                            <td>Amyloid PET signal (amyloid tracer uptake); cerebrospinal fluid Aβ (typically Aβ42 or Aβ42/Aβ40 ratios) as indicators of brain amyloid deposition.</td>
                        </tr>
                        <tr>
                            <td><strong>detection_performance</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_stage</strong></td>
                            <td>Preclinical through dementia; PET/CSF used for early detection and staging (preclinical, prodromal/MCI, dementia).</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>Review (summarizing human neuropathology, PET/CSF biomarker studies, and clinical trials).</td>
                        </tr>
                        <tr>
                            <td><strong>limitations_or_counter_evidence</strong></td>
                            <td>Review notes challenges: need for very early intervention to affect clinical outcomes; several anti-amyloid trials (e.g., solanezumab, bapineuzumab) failed to show clinical efficacy in phase 3, indicating that Aβ removal alone may be insufficient or too late. Specificity of amyloid to cognitive status and timing of intervention are limitations; numerical performance metrics are not provided in this review.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': "Alzheimer's Disease-A Comprehensive Review", 'publication_date_yy_mm': '2024-02'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e3890.1">
                <h3 class="extraction-instance">Extracted Data Instance 1 (e3890.1)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed causes or mechanisms of Alzheimer's disease, and any methods or biomarkers used for its detection, including evidence, results, and limitations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Tau</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Hyperphosphorylated tau / Neurofibrillary tangles</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Intraneuronal accumulation of hyperphosphorylated tau protein forming neurofibrillary tangles that destabilize microtubules and impair neuronal transport, strongly associated with neurodegeneration and clinical progression.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_cause</strong></td>
                            <td>Abnormal hyperphosphorylation, aggregation and spread of tau protein within neurons leading to neurofibrillary tangles, microtubule destabilization, synaptic dysfunction, and neuronal death.</td>
                        </tr>
                        <tr>
                            <td><strong>cause_evidence</strong></td>
                            <td>Review cites neuropathologic characterization of neurofibrillary tangles composed of hyperphosphorylated tau and references translational/clinical development work on tau (Holtzman et al.). Tau pathology is correlated with neuronal dysfunction and brain region atrophy in human studies; anti-tau therapeutic efforts and a phase 3 tau-aggregation inhibitor trial (Gauthier et al.) are noted. Evidence summarized is from human neuropathology and clinical trial literature (review level).</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>Tau PET imaging; CSF phosphorylated-tau (p-tau) assays</td>
                        </tr>
                        <tr>
                            <td><strong>biomarker_or_finding</strong></td>
                            <td>Tau PET tracer uptake; CSF total tau and phosphorylated tau (p-tau) levels.</td>
                        </tr>
                        <tr>
                            <td><strong>detection_performance</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_stage</strong></td>
                            <td>Effective for prodromal/MCI and dementia stages and increasingly used to identify tau pathology in preclinical staging frameworks.</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>Review (summarizing neuropathology, PET and CSF biomarker studies, and clinical trials).</td>
                        </tr>
                        <tr>
                            <td><strong>limitations_or_counter_evidence</strong></td>
                            <td>Review mentions that tau-targeting therapies are under investigation and that trial results (e.g., tau aggregation inhibitors) have had mixed outcomes; it emphasizes the need for further research. Quantitative performance metrics are not provided here.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': "Alzheimer's Disease-A Comprehensive Review", 'publication_date_yy_mm': '2024-02'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e3890.2">
                <h3 class="extraction-instance">Extracted Data Instance 2 (e3890.2)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed causes or mechanisms of Alzheimer's disease, and any methods or biomarkers used for its detection, including evidence, results, and limitations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Neuroinflammation</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Neuroinflammatory processes / Microglial activation</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Inflammatory responses in the brain, including microglial activation, are implicated as contributors and potential amplifiers of AD pathology and neuronal injury.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_cause</strong></td>
                            <td>Chronic neuroinflammation and maladaptive microglial responses that exacerbate amyloid and tau pathology and contribute to neuronal damage.</td>
                        </tr>
                        <tr>
                            <td><strong>cause_evidence</strong></td>
                            <td>Review cites literature (Heneka et al.) describing neuroinflammation as a key component of AD pathogenesis; evidence summarized includes human neuropathology and experimental studies showing inflammatory mediators alongside plaques/tangles. Therapeutic approaches to modulate inflammation (NSAIDs, other anti-inflammatory strategies) are discussed, with referenced randomized trials (e.g., rofecoxib/naproxen) showing limited or negative effects.</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>Not specified in detail in this review; inflammatory biomarkers in CSF or PET markers of microglial activation are implied areas of study.</td>
                        </tr>
                        <tr>
                            <td><strong>biomarker_or_finding</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_performance</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_stage</strong></td>
                            <td>Described across disease stages; relevance in progression and as a therapeutic target emphasized.</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>Review summarizing human and experimental evidence.</td>
                        </tr>
                        <tr>
                            <td><strong>limitations_or_counter_evidence</strong></td>
                            <td>Clinical trials of anti-inflammatory drugs cited had negative or inconclusive results; review notes the complexity of inflammation (timing, targets) and that modulation has not yet produced clear clinical benefits. Specific biomarker performance not provided.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': "Alzheimer's Disease-A Comprehensive Review", 'publication_date_yy_mm': '2024-02'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e3890.3">
                <h3 class="extraction-instance">Extracted Data Instance 3 (e3890.3)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed causes or mechanisms of Alzheimer's disease, and any methods or biomarkers used for its detection, including evidence, results, and limitations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>APOE ε4</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Apolipoprotein E epsilon-4 allele</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>A genetic risk factor that increases susceptibility to late-onset AD and influences amyloid deposition and disease trajectory.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_cause</strong></td>
                            <td>APOE ε4 allele increases risk for AD, likely by affecting amyloid processing/clearance and lipid transport, and interacting with environmental factors.</td>
                        </tr>
                        <tr>
                            <td><strong>cause_evidence</strong></td>
                            <td>Review cites genetic studies highlighting APOE as a major susceptibility gene; discusses interactions with environmental exposures (e.g., air pollution) and contribution to amyloidogenesis (citing Cacciottolo et al.). Evidence consists of large human genetic association studies and translational models mentioned in cited literature.</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>Genetic testing for APOE genotype</td>
                        </tr>
                        <tr>
                            <td><strong>biomarker_or_finding</strong></td>
                            <td>APOE genotype (presence of ε4 allele)</td>
                        </tr>
                        <tr>
                            <td><strong>detection_performance</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_stage</strong></td>
                            <td>Risk stratification across lifespan; relevant for preclinical risk assessment and precision medicine grouping.</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>Review citing human genetic association studies and translational models.</td>
                        </tr>
                        <tr>
                            <td><strong>limitations_or_counter_evidence</strong></td>
                            <td>APOE ε4 is a risk factor, not a deterministic cause; presence increases probability but many ε4 carriers do not develop AD and non-ε4 carriers can develop AD. Ethical/practical limitations of using APOE for prediction are implied; no performance metrics provided in this review.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': "Alzheimer's Disease-A Comprehensive Review", 'publication_date_yy_mm': '2024-02'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e3890.4">
                <h3 class="extraction-instance">Extracted Data Instance 4 (e3890.4)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed causes or mechanisms of Alzheimer's disease, and any methods or biomarkers used for its detection, including evidence, results, and limitations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Vascular contributions</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Vascular risk factors and cerebrovascular contributions to cognitive impairment and dementia</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Cardiovascular and cerebrovascular disease (hypertension, diabetes, hyperlipidemia, stroke) contribute to cognitive decline and interact with AD pathology to worsen outcomes.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_cause</strong></td>
                            <td>Chronic vascular disease and cerebrovascular pathology promote brain injury and reduce reserve, interacting with amyloid/tau pathology to produce or exacerbate cognitive impairment.</td>
                        </tr>
                        <tr>
                            <td><strong>cause_evidence</strong></td>
                            <td>Review references the American Heart Association/American Stroke Association statement (Gorelick et al.) describing vascular contributions to cognitive impairment; epidemiologic and clinical data linking hypertension, diabetes, and high cholesterol to increased AD risk are summarized. Evidence is from human epidemiology and clinical consensus statements.</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>Clinical cardiovascular risk assessment; neuroimaging for vascular lesions (implied, e.g., MRI); vascular risk monitoring in multidomain prevention trials</td>
                        </tr>
                        <tr>
                            <td><strong>biomarker_or_finding</strong></td>
                            <td>Vascular risk factor measures (blood pressure, glucose, lipids); imaging evidence of vascular lesions (white matter hyperintensities) implied though not detailed.</td>
                        </tr>
                        <tr>
                            <td><strong>detection_performance</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_stage</strong></td>
                            <td>Relevant across lifespan and in preclinical/MCI stages for prevention strategies.</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>Review citing epidemiologic and clinical guideline/literature.</td>
                        </tr>
                        <tr>
                            <td><strong>limitations_or_counter_evidence</strong></td>
                            <td>Vascular risk is a modifiable contributor but not the sole cause; interplay with AD pathology complicates attribution. The review does not provide quantitative predictive performance for vascular markers.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': "Alzheimer's Disease-A Comprehensive Review", 'publication_date_yy_mm': '2024-02'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e3890.5">
                <h3 class="extraction-instance">Extracted Data Instance 5 (e3890.5)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed causes or mechanisms of Alzheimer's disease, and any methods or biomarkers used for its detection, including evidence, results, and limitations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Environmental exposures</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Air pollution and toxic environmental exposures (e.g., particulate matter, heavy metals)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Environmental pollutants are discussed as contributing factors that may increase amyloidogenesis and cognitive impairment, potentially modifying AD risk.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_cause</strong></td>
                            <td>Exposure to air pollution and certain toxins/heavy metals may increase AD risk through neuroinflammatory and amyloidogenic mechanisms.</td>
                        </tr>
                        <tr>
                            <td><strong>cause_evidence</strong></td>
                            <td>Review cites studies (e.g., Cacciottolo et al.) showing associations between particulate air pollutants, APOE alleles, and cognitive impairment in older women and experimental models showing increased amyloidogenesis. Evidence includes human epidemiologic associations and experimental animal/model data reported in cited literature.</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>Epidemiologic exposure assessment (air pollution metrics); not a diagnostic detection method for AD per se.</td>
                        </tr>
                        <tr>
                            <td><strong>biomarker_or_finding</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_performance</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_stage</strong></td>
                            <td>Risk/exposure influence across midlife to late life; implicated in processes leading to preclinical pathology.</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>Review summarizing epidemiologic and experimental studies.</td>
                        </tr>
                        <tr>
                            <td><strong>limitations_or_counter_evidence</strong></td>
                            <td>Associations may be confounded; mechanistic pathways are suggested by experimental models but causality in humans is not definitively proven. The review notes environmental factors as contributors but does not provide quantitative effect sizes in this text.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': "Alzheimer's Disease-A Comprehensive Review", 'publication_date_yy_mm': '2024-02'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e3890.6">
                <h3 class="extraction-instance">Extracted Data Instance 6 (e3890.6)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed causes or mechanisms of Alzheimer's disease, and any methods or biomarkers used for its detection, including evidence, results, and limitations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Synaptic / Neurotransmitter dysfunction</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Synaptic loss and neurotransmitter system dysfunction (acetylcholine and glutamate)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Loss of synapses and disruption of neurotransmitter systems (notably cholinergic and glutamatergic) are described as central to cognitive symptoms in AD.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_cause</strong></td>
                            <td>Synaptic degeneration and neurotransmitter deficits (acetylcholine loss, glutamatergic dysfunction) lead directly to cognitive impairment and are downstream effects of core AD pathologies.</td>
                        </tr>
                        <tr>
                            <td><strong>cause_evidence</strong></td>
                            <td>Review summarizes neuropathological and clinical pharmacologic evidence: cholinesterase inhibitors (donepezil, rivastigmine, galantamine) and memantine (NMDA antagonist) provide symptomatic benefit, supporting the role of cholinergic and glutamatergic dysfunction. Evidence cited is from clinical trials and neuropathology summarized in the review.</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>Clinical cognitive testing and response to symptomatic therapies; not a specific biomarker detailed in the review.</td>
                        </tr>
                        <tr>
                            <td><strong>biomarker_or_finding</strong></td>
                            <td>Clinical features of synaptic/neurotransmitter dysfunction (memory loss, impaired cognition); therapeutic response used diagnostically in practice but no specific biochemical marker provided here.</td>
                        </tr>
                        <tr>
                            <td><strong>detection_performance</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_stage</strong></td>
                            <td>Primarily symptomatic stages (MCI to dementia) where neurotransmitter deficits manifest.</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>Review summarizing clinical trials and neuropathology.</td>
                        </tr>
                        <tr>
                            <td><strong>limitations_or_counter_evidence</strong></td>
                            <td>Symptomatic therapies do not halt disease progression; synaptic/neurotransmitter deficits are downstream and not necessarily specific to AD, limiting diagnostic specificity.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': "Alzheimer's Disease-A Comprehensive Review", 'publication_date_yy_mm': '2024-02'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e3890.7">
                <h3 class="extraction-instance">Extracted Data Instance 7 (e3890.7)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed causes or mechanisms of Alzheimer's disease, and any methods or biomarkers used for its detection, including evidence, results, and limitations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Amyloid/Tau PET</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Positron emission tomography imaging of amyloid-beta and tau proteins</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>PET imaging using tracers for amyloid or tau provides in vivo detection of hallmark AD pathologies and is used for diagnosis and monitoring in research and some clinical settings.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_cause</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>cause_evidence</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>Amyloid PET and tau PET imaging</td>
                        </tr>
                        <tr>
                            <td><strong>biomarker_or_finding</strong></td>
                            <td>Tracer uptake patterns indicating brain amyloid deposition (amyloid PET) and tau neurofibrillary pathology (tau PET).</td>
                        </tr>
                        <tr>
                            <td><strong>detection_performance</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_stage</strong></td>
                            <td>Used from preclinical stages (amyloid PET positivity) through symptomatic stages to characterize pathology and for staging in research/diagnostic frameworks.</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>Review summarizing neuroimaging literature (human PET studies).</td>
                        </tr>
                        <tr>
                            <td><strong>limitations_or_counter_evidence</strong></td>
                            <td>Review notes PET enhances early detection and monitoring but does not provide numerical sensitivity/specificity in this text; practical limitations include cost, availability, and PET tracer/interpretation variability. The review emphasizes PET as a research and diagnostic advance but notes need for integration with other biomarkers.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': "Alzheimer's Disease-A Comprehensive Review", 'publication_date_yy_mm': '2024-02'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e3890.8">
                <h3 class="extraction-instance">Extracted Data Instance 8 (e3890.8)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed causes or mechanisms of Alzheimer's disease, and any methods or biomarkers used for its detection, including evidence, results, and limitations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>CSF biomarkers</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Cerebrospinal fluid amyloid and tau assays</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>CSF assays measuring Aβ, total tau, and phosphorylated tau are established biomarkers reflecting brain amyloid and tau pathology and are used for diagnosis and staging.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_cause</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>cause_evidence</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>Cerebrospinal fluid (CSF) biomarker analysis</td>
                        </tr>
                        <tr>
                            <td><strong>biomarker_or_finding</strong></td>
                            <td>CSF Aβ (often Aβ42 or Aβ42/Aβ40), total tau, and phosphorylated tau (p-tau) concentrations.</td>
                        </tr>
                        <tr>
                            <td><strong>detection_performance</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_stage</strong></td>
                            <td>Preclinical, prodromal/MCI and dementia stages useful for biomarker-based diagnosis and monitoring.</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>Review summarizing clinical/biomarker literature.</td>
                        </tr>
                        <tr>
                            <td><strong>limitations_or_counter_evidence</strong></td>
                            <td>Invasiveness of lumbar puncture limits widespread use; assay standardization and cutoffs can vary. The review does not provide specific sensitivity/specificity values.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': "Alzheimer's Disease-A Comprehensive Review", 'publication_date_yy_mm': '2024-02'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e3890.9">
                <h3 class="extraction-instance">Extracted Data Instance 9 (e3890.9)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed causes or mechanisms of Alzheimer's disease, and any methods or biomarkers used for its detection, including evidence, results, and limitations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Plasma P-tau181</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Plasma phosphorylated tau at threonine 181 (P-tau181)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>A blood-based biomarker increasingly reported to correlate with CSF and PET measures of tau and to predict progression to Alzheimer's dementia.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Plasma P-tau181 in Alzheimer's disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer's dementia.</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_cause</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>cause_evidence</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>Blood plasma assay for phosphorylated tau (p-tau181)</td>
                        </tr>
                        <tr>
                            <td><strong>biomarker_or_finding</strong></td>
                            <td>Elevated plasma P-tau181 associated with AD pathology and longitudinal progression to AD dementia, and correlated with CSF/PET markers (cited Janelidze et al., Nat Med 2020).</td>
                        </tr>
                        <tr>
                            <td><strong>detection_performance</strong></td>
                            <td>This review references the Janelidze et al. study but does not report numerical sensitivity/specificity/AUC values; the cited study reports relationships and progression associations (numerical metrics not included in this review).</td>
                        </tr>
                        <tr>
                            <td><strong>detection_stage</strong></td>
                            <td>Useful for differential diagnosis and predicting longitudinal progression from preclinical/MCI to Alzheimer's dementia according to cited work.</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>Review citing a human biomarker study (Janelidze et al. 2020) and summarizing biomarker research.</td>
                        </tr>
                        <tr>
                            <td><strong>limitations_or_counter_evidence</strong></td>
                            <td>Review notes plasma p-tau181 is promising but does not provide detailed performance metrics here; external validation, assay standardization, and translation into clinical practice remain challenges.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': "Alzheimer's Disease-A Comprehensive Review", 'publication_date_yy_mm': '2024-02'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e3890.10">
                <h3 class="extraction-instance">Extracted Data Instance 10 (e3890.10)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed causes or mechanisms of Alzheimer's disease, and any methods or biomarkers used for its detection, including evidence, results, and limitations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Cognitive testing / Cognitive reserve</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Clinical cognitive tests and the cognitive reserve concept</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Clinical cognitive assessments and the concept of cognitive reserve (education/engagement) are used for risk assessment, staging, and understanding resilience to AD pathology.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_cause</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>cause_evidence</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>Neuropsychological tests and assessment of cognitive reserve (education, lifelong cognitive engagement); used clinically to detect cognitive impairment.</td>
                        </tr>
                        <tr>
                            <td><strong>biomarker_or_finding</strong></td>
                            <td>Cognitive test performance (e.g., MMSE and other neuropsychological batteries) and proxies for cognitive reserve (education level, activity).</td>
                        </tr>
                        <tr>
                            <td><strong>detection_performance</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_stage</strong></td>
                            <td>Primarily useful in symptomatic stages (MCI and dementia) but also used longitudinally in prevention trials to detect decline.</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>Review citing epidemiologic and clinical intervention studies (e.g., FINGER trial, observational studies on cognitive reserve).</td>
                        </tr>
                        <tr>
                            <td><strong>limitations_or_counter_evidence</strong></td>
                            <td>Cognitive tests are influenced by education, cultural factors, and reserve, reducing specificity; cognitive reserve can mask pathology and delay clinical detection; review does not provide performance metrics.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': "Alzheimer's Disease-A Comprehensive Review", 'publication_date_yy_mm': '2024-02'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
        </div>

        <div class="section">
            <h2>Potentially Relevant New Papers (mentioned by this paper)</h2>
            <ol>
                <li>The amyloid hypothesis of Alzheimer's disease at 25 years <em>(Rating: 2)</em></li>
                <li>The amyloid cascade hypothesis <em>(Rating: 2)</em></li>
                <li>Tau: From research to clinical development <em>(Rating: 2)</em></li>
                <li>Neuroinflammation in Alzheimer's disease <em>(Rating: 2)</em></li>
                <li>Plasma P-tau181 in Alzheimer's disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer's dementia <em>(Rating: 2)</em></li>
                <li>Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the american heart association/american stroke association <em>(Rating: 2)</em></li>
                <li>Particulate air pollutants, APOE alleles and their contributions to cognitive impairment in older women and to amyloidogenesis in experimental models <em>(Rating: 2)</em></li>
                <li>Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease <em>(Rating: 2)</em></li>
                <li>Toward a biological definition of Alzheimer's disease <em>(Rating: 2)</em></li>
                <li>A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial <em>(Rating: 1)</em></li>
            </ol>
        </div>

        <div class="section">
            <h2>Extracted Data (Debug)</h2>
            <pre><code>{
    "id": "extraction-result-3890",
    "paper_id": "paper-267515482",
    "extraction_schema_id": "extraction-schema-94",
    "extracted_data": [
        {
            "name_short": "Aβ / Amyloid-beta",
            "name_full": "Amyloid-beta peptide accumulation / Amyloid cascade hypothesis",
            "brief_description": "Extracellular aggregation of amyloid-beta peptides into plaques is presented as a central proposed mechanism in AD, thought to disrupt synapses and trigger downstream neurodegeneration and inflammation.",
            "citation_title": "",
            "mention_or_use": "mention",
            "proposed_cause": "Accumulation and aggregation of amyloid-beta peptides (amyloid plaques) driving synaptic dysfunction and downstream neurodegeneration (the amyloid cascade hypothesis).",
            "cause_evidence": "Review cites historical neuropathology showing amyloid plaque cores composed of aggregated Aβ (Masters et al., 1985) and summarizes the amyloid cascade hypothesis (Hardy & Higgins 1992; Selkoe & Hardy 2016). Evidence referenced includes neuropathologic observations in humans and experimental models linking amyloid to synaptic disruption and neuroinflammation; clinical trials targeting Aβ (e.g., aducanumab, solanezumab, bapineuzumab) are noted, with mixed/limited clinical benefit reported in phase 3 trials (Doody et al.; Honig et al.). The paper is a review (no new primary data).",
            "detection_method": "Amyloid PET imaging; CSF Aβ measurements",
            "biomarker_or_finding": "Amyloid PET signal (amyloid tracer uptake); cerebrospinal fluid Aβ (typically Aβ42 or Aβ42/Aβ40 ratios) as indicators of brain amyloid deposition.",
            "detection_performance": null,
            "detection_stage": "Preclinical through dementia; PET/CSF used for early detection and staging (preclinical, prodromal/MCI, dementia).",
            "study_type": "Review (summarizing human neuropathology, PET/CSF biomarker studies, and clinical trials).",
            "limitations_or_counter_evidence": "Review notes challenges: need for very early intervention to affect clinical outcomes; several anti-amyloid trials (e.g., solanezumab, bapineuzumab) failed to show clinical efficacy in phase 3, indicating that Aβ removal alone may be insufficient or too late. Specificity of amyloid to cognitive status and timing of intervention are limitations; numerical performance metrics are not provided in this review.",
            "uuid": "e3890.0",
            "source_info": {
                "paper_title": "Alzheimer's Disease-A Comprehensive Review",
                "publication_date_yy_mm": "2024-02"
            }
        },
        {
            "name_short": "Tau",
            "name_full": "Hyperphosphorylated tau / Neurofibrillary tangles",
            "brief_description": "Intraneuronal accumulation of hyperphosphorylated tau protein forming neurofibrillary tangles that destabilize microtubules and impair neuronal transport, strongly associated with neurodegeneration and clinical progression.",
            "citation_title": "",
            "mention_or_use": "mention",
            "proposed_cause": "Abnormal hyperphosphorylation, aggregation and spread of tau protein within neurons leading to neurofibrillary tangles, microtubule destabilization, synaptic dysfunction, and neuronal death.",
            "cause_evidence": "Review cites neuropathologic characterization of neurofibrillary tangles composed of hyperphosphorylated tau and references translational/clinical development work on tau (Holtzman et al.). Tau pathology is correlated with neuronal dysfunction and brain region atrophy in human studies; anti-tau therapeutic efforts and a phase 3 tau-aggregation inhibitor trial (Gauthier et al.) are noted. Evidence summarized is from human neuropathology and clinical trial literature (review level).",
            "detection_method": "Tau PET imaging; CSF phosphorylated-tau (p-tau) assays",
            "biomarker_or_finding": "Tau PET tracer uptake; CSF total tau and phosphorylated tau (p-tau) levels.",
            "detection_performance": null,
            "detection_stage": "Effective for prodromal/MCI and dementia stages and increasingly used to identify tau pathology in preclinical staging frameworks.",
            "study_type": "Review (summarizing neuropathology, PET and CSF biomarker studies, and clinical trials).",
            "limitations_or_counter_evidence": "Review mentions that tau-targeting therapies are under investigation and that trial results (e.g., tau aggregation inhibitors) have had mixed outcomes; it emphasizes the need for further research. Quantitative performance metrics are not provided here.",
            "uuid": "e3890.1",
            "source_info": {
                "paper_title": "Alzheimer's Disease-A Comprehensive Review",
                "publication_date_yy_mm": "2024-02"
            }
        },
        {
            "name_short": "Neuroinflammation",
            "name_full": "Neuroinflammatory processes / Microglial activation",
            "brief_description": "Inflammatory responses in the brain, including microglial activation, are implicated as contributors and potential amplifiers of AD pathology and neuronal injury.",
            "citation_title": "",
            "mention_or_use": "mention",
            "proposed_cause": "Chronic neuroinflammation and maladaptive microglial responses that exacerbate amyloid and tau pathology and contribute to neuronal damage.",
            "cause_evidence": "Review cites literature (Heneka et al.) describing neuroinflammation as a key component of AD pathogenesis; evidence summarized includes human neuropathology and experimental studies showing inflammatory mediators alongside plaques/tangles. Therapeutic approaches to modulate inflammation (NSAIDs, other anti-inflammatory strategies) are discussed, with referenced randomized trials (e.g., rofecoxib/naproxen) showing limited or negative effects.",
            "detection_method": "Not specified in detail in this review; inflammatory biomarkers in CSF or PET markers of microglial activation are implied areas of study.",
            "biomarker_or_finding": null,
            "detection_performance": null,
            "detection_stage": "Described across disease stages; relevance in progression and as a therapeutic target emphasized.",
            "study_type": "Review summarizing human and experimental evidence.",
            "limitations_or_counter_evidence": "Clinical trials of anti-inflammatory drugs cited had negative or inconclusive results; review notes the complexity of inflammation (timing, targets) and that modulation has not yet produced clear clinical benefits. Specific biomarker performance not provided.",
            "uuid": "e3890.2",
            "source_info": {
                "paper_title": "Alzheimer's Disease-A Comprehensive Review",
                "publication_date_yy_mm": "2024-02"
            }
        },
        {
            "name_short": "APOE ε4",
            "name_full": "Apolipoprotein E epsilon-4 allele",
            "brief_description": "A genetic risk factor that increases susceptibility to late-onset AD and influences amyloid deposition and disease trajectory.",
            "citation_title": "",
            "mention_or_use": "mention",
            "proposed_cause": "APOE ε4 allele increases risk for AD, likely by affecting amyloid processing/clearance and lipid transport, and interacting with environmental factors.",
            "cause_evidence": "Review cites genetic studies highlighting APOE as a major susceptibility gene; discusses interactions with environmental exposures (e.g., air pollution) and contribution to amyloidogenesis (citing Cacciottolo et al.). Evidence consists of large human genetic association studies and translational models mentioned in cited literature.",
            "detection_method": "Genetic testing for APOE genotype",
            "biomarker_or_finding": "APOE genotype (presence of ε4 allele)",
            "detection_performance": null,
            "detection_stage": "Risk stratification across lifespan; relevant for preclinical risk assessment and precision medicine grouping.",
            "study_type": "Review citing human genetic association studies and translational models.",
            "limitations_or_counter_evidence": "APOE ε4 is a risk factor, not a deterministic cause; presence increases probability but many ε4 carriers do not develop AD and non-ε4 carriers can develop AD. Ethical/practical limitations of using APOE for prediction are implied; no performance metrics provided in this review.",
            "uuid": "e3890.3",
            "source_info": {
                "paper_title": "Alzheimer's Disease-A Comprehensive Review",
                "publication_date_yy_mm": "2024-02"
            }
        },
        {
            "name_short": "Vascular contributions",
            "name_full": "Vascular risk factors and cerebrovascular contributions to cognitive impairment and dementia",
            "brief_description": "Cardiovascular and cerebrovascular disease (hypertension, diabetes, hyperlipidemia, stroke) contribute to cognitive decline and interact with AD pathology to worsen outcomes.",
            "citation_title": "",
            "mention_or_use": "mention",
            "proposed_cause": "Chronic vascular disease and cerebrovascular pathology promote brain injury and reduce reserve, interacting with amyloid/tau pathology to produce or exacerbate cognitive impairment.",
            "cause_evidence": "Review references the American Heart Association/American Stroke Association statement (Gorelick et al.) describing vascular contributions to cognitive impairment; epidemiologic and clinical data linking hypertension, diabetes, and high cholesterol to increased AD risk are summarized. Evidence is from human epidemiology and clinical consensus statements.",
            "detection_method": "Clinical cardiovascular risk assessment; neuroimaging for vascular lesions (implied, e.g., MRI); vascular risk monitoring in multidomain prevention trials",
            "biomarker_or_finding": "Vascular risk factor measures (blood pressure, glucose, lipids); imaging evidence of vascular lesions (white matter hyperintensities) implied though not detailed.",
            "detection_performance": null,
            "detection_stage": "Relevant across lifespan and in preclinical/MCI stages for prevention strategies.",
            "study_type": "Review citing epidemiologic and clinical guideline/literature.",
            "limitations_or_counter_evidence": "Vascular risk is a modifiable contributor but not the sole cause; interplay with AD pathology complicates attribution. The review does not provide quantitative predictive performance for vascular markers.",
            "uuid": "e3890.4",
            "source_info": {
                "paper_title": "Alzheimer's Disease-A Comprehensive Review",
                "publication_date_yy_mm": "2024-02"
            }
        },
        {
            "name_short": "Environmental exposures",
            "name_full": "Air pollution and toxic environmental exposures (e.g., particulate matter, heavy metals)",
            "brief_description": "Environmental pollutants are discussed as contributing factors that may increase amyloidogenesis and cognitive impairment, potentially modifying AD risk.",
            "citation_title": "",
            "mention_or_use": "mention",
            "proposed_cause": "Exposure to air pollution and certain toxins/heavy metals may increase AD risk through neuroinflammatory and amyloidogenic mechanisms.",
            "cause_evidence": "Review cites studies (e.g., Cacciottolo et al.) showing associations between particulate air pollutants, APOE alleles, and cognitive impairment in older women and experimental models showing increased amyloidogenesis. Evidence includes human epidemiologic associations and experimental animal/model data reported in cited literature.",
            "detection_method": "Epidemiologic exposure assessment (air pollution metrics); not a diagnostic detection method for AD per se.",
            "biomarker_or_finding": null,
            "detection_performance": null,
            "detection_stage": "Risk/exposure influence across midlife to late life; implicated in processes leading to preclinical pathology.",
            "study_type": "Review summarizing epidemiologic and experimental studies.",
            "limitations_or_counter_evidence": "Associations may be confounded; mechanistic pathways are suggested by experimental models but causality in humans is not definitively proven. The review notes environmental factors as contributors but does not provide quantitative effect sizes in this text.",
            "uuid": "e3890.5",
            "source_info": {
                "paper_title": "Alzheimer's Disease-A Comprehensive Review",
                "publication_date_yy_mm": "2024-02"
            }
        },
        {
            "name_short": "Synaptic / Neurotransmitter dysfunction",
            "name_full": "Synaptic loss and neurotransmitter system dysfunction (acetylcholine and glutamate)",
            "brief_description": "Loss of synapses and disruption of neurotransmitter systems (notably cholinergic and glutamatergic) are described as central to cognitive symptoms in AD.",
            "citation_title": "",
            "mention_or_use": "mention",
            "proposed_cause": "Synaptic degeneration and neurotransmitter deficits (acetylcholine loss, glutamatergic dysfunction) lead directly to cognitive impairment and are downstream effects of core AD pathologies.",
            "cause_evidence": "Review summarizes neuropathological and clinical pharmacologic evidence: cholinesterase inhibitors (donepezil, rivastigmine, galantamine) and memantine (NMDA antagonist) provide symptomatic benefit, supporting the role of cholinergic and glutamatergic dysfunction. Evidence cited is from clinical trials and neuropathology summarized in the review.",
            "detection_method": "Clinical cognitive testing and response to symptomatic therapies; not a specific biomarker detailed in the review.",
            "biomarker_or_finding": "Clinical features of synaptic/neurotransmitter dysfunction (memory loss, impaired cognition); therapeutic response used diagnostically in practice but no specific biochemical marker provided here.",
            "detection_performance": null,
            "detection_stage": "Primarily symptomatic stages (MCI to dementia) where neurotransmitter deficits manifest.",
            "study_type": "Review summarizing clinical trials and neuropathology.",
            "limitations_or_counter_evidence": "Symptomatic therapies do not halt disease progression; synaptic/neurotransmitter deficits are downstream and not necessarily specific to AD, limiting diagnostic specificity.",
            "uuid": "e3890.6",
            "source_info": {
                "paper_title": "Alzheimer's Disease-A Comprehensive Review",
                "publication_date_yy_mm": "2024-02"
            }
        },
        {
            "name_short": "Amyloid/Tau PET",
            "name_full": "Positron emission tomography imaging of amyloid-beta and tau proteins",
            "brief_description": "PET imaging using tracers for amyloid or tau provides in vivo detection of hallmark AD pathologies and is used for diagnosis and monitoring in research and some clinical settings.",
            "citation_title": "",
            "mention_or_use": "mention",
            "proposed_cause": null,
            "cause_evidence": null,
            "detection_method": "Amyloid PET and tau PET imaging",
            "biomarker_or_finding": "Tracer uptake patterns indicating brain amyloid deposition (amyloid PET) and tau neurofibrillary pathology (tau PET).",
            "detection_performance": null,
            "detection_stage": "Used from preclinical stages (amyloid PET positivity) through symptomatic stages to characterize pathology and for staging in research/diagnostic frameworks.",
            "study_type": "Review summarizing neuroimaging literature (human PET studies).",
            "limitations_or_counter_evidence": "Review notes PET enhances early detection and monitoring but does not provide numerical sensitivity/specificity in this text; practical limitations include cost, availability, and PET tracer/interpretation variability. The review emphasizes PET as a research and diagnostic advance but notes need for integration with other biomarkers.",
            "uuid": "e3890.7",
            "source_info": {
                "paper_title": "Alzheimer's Disease-A Comprehensive Review",
                "publication_date_yy_mm": "2024-02"
            }
        },
        {
            "name_short": "CSF biomarkers",
            "name_full": "Cerebrospinal fluid amyloid and tau assays",
            "brief_description": "CSF assays measuring Aβ, total tau, and phosphorylated tau are established biomarkers reflecting brain amyloid and tau pathology and are used for diagnosis and staging.",
            "citation_title": "",
            "mention_or_use": "mention",
            "proposed_cause": null,
            "cause_evidence": null,
            "detection_method": "Cerebrospinal fluid (CSF) biomarker analysis",
            "biomarker_or_finding": "CSF Aβ (often Aβ42 or Aβ42/Aβ40), total tau, and phosphorylated tau (p-tau) concentrations.",
            "detection_performance": null,
            "detection_stage": "Preclinical, prodromal/MCI and dementia stages useful for biomarker-based diagnosis and monitoring.",
            "study_type": "Review summarizing clinical/biomarker literature.",
            "limitations_or_counter_evidence": "Invasiveness of lumbar puncture limits widespread use; assay standardization and cutoffs can vary. The review does not provide specific sensitivity/specificity values.",
            "uuid": "e3890.8",
            "source_info": {
                "paper_title": "Alzheimer's Disease-A Comprehensive Review",
                "publication_date_yy_mm": "2024-02"
            }
        },
        {
            "name_short": "Plasma P-tau181",
            "name_full": "Plasma phosphorylated tau at threonine 181 (P-tau181)",
            "brief_description": "A blood-based biomarker increasingly reported to correlate with CSF and PET measures of tau and to predict progression to Alzheimer's dementia.",
            "citation_title": "Plasma P-tau181 in Alzheimer's disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer's dementia.",
            "mention_or_use": "mention",
            "proposed_cause": null,
            "cause_evidence": null,
            "detection_method": "Blood plasma assay for phosphorylated tau (p-tau181)",
            "biomarker_or_finding": "Elevated plasma P-tau181 associated with AD pathology and longitudinal progression to AD dementia, and correlated with CSF/PET markers (cited Janelidze et al., Nat Med 2020).",
            "detection_performance": "This review references the Janelidze et al. study but does not report numerical sensitivity/specificity/AUC values; the cited study reports relationships and progression associations (numerical metrics not included in this review).",
            "detection_stage": "Useful for differential diagnosis and predicting longitudinal progression from preclinical/MCI to Alzheimer's dementia according to cited work.",
            "study_type": "Review citing a human biomarker study (Janelidze et al. 2020) and summarizing biomarker research.",
            "limitations_or_counter_evidence": "Review notes plasma p-tau181 is promising but does not provide detailed performance metrics here; external validation, assay standardization, and translation into clinical practice remain challenges.",
            "uuid": "e3890.9",
            "source_info": {
                "paper_title": "Alzheimer's Disease-A Comprehensive Review",
                "publication_date_yy_mm": "2024-02"
            }
        },
        {
            "name_short": "Cognitive testing / Cognitive reserve",
            "name_full": "Clinical cognitive tests and the cognitive reserve concept",
            "brief_description": "Clinical cognitive assessments and the concept of cognitive reserve (education/engagement) are used for risk assessment, staging, and understanding resilience to AD pathology.",
            "citation_title": "",
            "mention_or_use": "mention",
            "proposed_cause": null,
            "cause_evidence": null,
            "detection_method": "Neuropsychological tests and assessment of cognitive reserve (education, lifelong cognitive engagement); used clinically to detect cognitive impairment.",
            "biomarker_or_finding": "Cognitive test performance (e.g., MMSE and other neuropsychological batteries) and proxies for cognitive reserve (education level, activity).",
            "detection_performance": null,
            "detection_stage": "Primarily useful in symptomatic stages (MCI and dementia) but also used longitudinally in prevention trials to detect decline.",
            "study_type": "Review citing epidemiologic and clinical intervention studies (e.g., FINGER trial, observational studies on cognitive reserve).",
            "limitations_or_counter_evidence": "Cognitive tests are influenced by education, cultural factors, and reserve, reducing specificity; cognitive reserve can mask pathology and delay clinical detection; review does not provide performance metrics.",
            "uuid": "e3890.10",
            "source_info": {
                "paper_title": "Alzheimer's Disease-A Comprehensive Review",
                "publication_date_yy_mm": "2024-02"
            }
        }
    ],
    "potentially_relevant_new_papers": [
        {
            "paper_title": "The amyloid hypothesis of Alzheimer's disease at 25 years",
            "rating": 2,
            "sanitized_title": "the_amyloid_hypothesis_of_alzheimers_disease_at_25_years"
        },
        {
            "paper_title": "The amyloid cascade hypothesis",
            "rating": 2,
            "sanitized_title": "the_amyloid_cascade_hypothesis"
        },
        {
            "paper_title": "Tau: From research to clinical development",
            "rating": 2,
            "sanitized_title": "tau_from_research_to_clinical_development"
        },
        {
            "paper_title": "Neuroinflammation in Alzheimer's disease",
            "rating": 2,
            "sanitized_title": "neuroinflammation_in_alzheimers_disease"
        },
        {
            "paper_title": "Plasma P-tau181 in Alzheimer's disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer's dementia",
            "rating": 2,
            "sanitized_title": "plasma_ptau181_in_alzheimers_disease_relationship_to_other_biomarkers_differential_diagnosis_neuropathology_and_longitudinal_progression_to_alzheimers_dementia"
        },
        {
            "paper_title": "Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the american heart association/american stroke association",
            "rating": 2,
            "sanitized_title": "vascular_contributions_to_cognitive_impairment_and_dementia_a_statement_for_healthcare_professionals_from_the_american_heart_associationamerican_stroke_association"
        },
        {
            "paper_title": "Particulate air pollutants, APOE alleles and their contributions to cognitive impairment in older women and to amyloidogenesis in experimental models",
            "rating": 2,
            "sanitized_title": "particulate_air_pollutants_apoe_alleles_and_their_contributions_to_cognitive_impairment_in_older_women_and_to_amyloidogenesis_in_experimental_models"
        },
        {
            "paper_title": "Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease",
            "rating": 2,
            "sanitized_title": "toward_defining_the_preclinical_stages_of_alzheimers_disease_recommendations_from_the_national_institute_on_agingalzheimers_association_workgroups_on_diagnostic_guidelines_for_alzheimers_disease"
        },
        {
            "paper_title": "Toward a biological definition of Alzheimer's disease",
            "rating": 2,
            "sanitized_title": "toward_a_biological_definition_of_alzheimers_disease"
        },
        {
            "paper_title": "A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial",
            "rating": 1,
            "sanitized_title": "a_2_year_multidomain_intervention_of_diet_exercise_cognitive_training_and_vascular_risk_monitoring_versus_control_to_prevent_cognitive_decline_in_atrisk_elderly_people_finger_a_randomised_controlled_trial"
        }
    ],
    "cost": 0.0125415,
    "model_str": "gpt-5-mini"
}</code></pre>
        </div>
        <div class="section">
            <h2>Paper</h2>
            <div class="paper-content"><p>Alzheimer's Disease-A Comprehensive Review</p>
<p>Kinga Woźniak kinga966@outlook.com 
Monika Gardian-Baj mgardianbaj@gmail.com 
Magdalena Jung magdalenamehel@gmail.com 
Patryk Hedesz p.hedesz@gmail.com 
Maximilian Jung max.jung@wp.pl 
Aleksandra Żuk-Łapan aleksandrazuk11@gmail.com 
Aleksandra Doryń aleksandradoryn@gmail.com 
Krystian Jędral kjedral@ihit.waw.pl 
Instytut Hematologii 
Transfuzjologii 
Warszawa Ul Indiry Gandhi 
Aleksandra Włodarczyk 
Szpital Miejski 
Specjalistyczny Im Gabriela Narutowicza 
Justyna Popczyńska jpopczynska@gmail.com </p>
<p>Medical University of Warsaw
ul. Żwirki i Wigury 6102-091Warsaw</p>
<p>Medical University of Warsaw
ul. Żwirki i Wigury 6102-091Warsaw</p>
<p>University Clinical Hospital
26 Wincentego Witosa Avenue45-401Opole, Opole</p>
<p>Medical University of Warsaw
ul. Żwirki i Wigury 6102-091Warsaw, email</p>
<p>University Clinical Hospital
26 Wincentego Witosa Avenue45-401Opole, Opole</p>
<p>Medical University of Warsaw
ul. Żwirki i Wigury 6102-091</p>
<p>Medical University of Warsaw
ul. Żwirki i Wigury 6102-091Warsaw</p>
<p>196 Alicja Szczerbiak
Medical University of Warsaw
ul. Żwirki i Wigury 6102-091Warsaw</p>
<p>Medical University of Warsaw
ul. Żwirki i Wigury 6102-091Warsaw</p>
<p>Alzheimer's Disease-A Comprehensive Review
e 2391-830675C9196C12F02C5ECE419FFA3B07CF6310.12775/JEHS.2024.56.013Alzheimer's diseasePsychiatryDementiaNeurodegeneration
Przypisane dyscypliny naukowe: Nauki o kulturze fizycznej (Dziedzina nauk medycznych i nauk o zdrowiu); Nauki o zdrowiu (Dziedzina nauk medycznych i nauk o zdrowiu).</p>
<p>Introduction:</p>
<p>Alzheimer's disease (AD) poses an escalating challenge in neurodegenerative disorders, becoming the predominant cause of dementia globally and imposing a growing burden on healthcare systems as populations age.With millions affected worldwide, including significant repercussions on individuals and caregivers, the evolving understanding of AD is underscored by ongoing research aimed at unraveling its intricate mechanisms.The disease's impact extends beyond individual suffering, permeating familial and societal structures, particularly as the aging global population anticipates a dramatic rise in AD prevalence.</p>
<p>Characterized historically by amyloid-beta plaques and tau tangles, recent advancements, including neuroimaging and biomarker studies, are reshaping the conceptualization of AD, revealing its multifactorial nature.[1,2] While age remains the primary risk factor, genetic predisposition and environmental influences, such as the APOE gene and factors ranging from air pollution to lifestyle choices, contribute layers of complexity to AD's etiology.The therapeutic landscape is witnessing significant strides, encompassing anti-amyloid therapies, innovative approaches targeting tau pathology, and the recognition of lifestyle interventions and precision medicine approaches, reflecting the dynamic nature of AD research.This comprehensive exploration delves into the current state of knowledge surrounding AD, synthesizing findings across diverse research domains, from risk factors to therapeutic strategies, emphasizing the pressing need for continued collaborative efforts in unraveling the mysteries of this complex and devastating neurological disorder.[3,4,5]</p>
<p>Pathological Features:</p>
<p>Alzheimer's disease, a neurodegenerative disorder, presents a complex array of pathological features that collectively contribute to its debilitating impact on cognitive function.The most prominent pathological features include the formation of extracellular beta-amyloid plaques and intracellular neurofibrillary tangles.Beta-amyloid plaques are composed of aggregated beta-amyloid peptides, which are fragments of the amyloid precursor protein.The accumulation of these plaques disrupts normal synaptic function and induces neuroinflammation, further exacerbating neuronal damage.Neurofibrillary tangles, on the other hand, consist mainly of hyperphosphorylated tau protein, leading to the formation of twisted filamentous structures within neurons.This tau pathology is associated with the destabilization of microtubules in the neuronal cytoskeleton, compromising cellular transport and structural integrity.</p>
<p>In addition to plaques and tangles, there is evidence of synaptic and neurotransmitter dysfunction in Alzheimer's disease.Disruptions in neurotransmitter systems, particularly acetylcholine and glutamate, contribute to synaptic failure and impair communication between neurons.Synaptic loss and neuronal damage, particularly in brain regions crucial for memory and cognitive functions such as the hippocampus and neocortex, are prominent features of the disease progression.Furthermore, alterations in the levels of other proteins, such as presenilins and apolipoprotein E (ApoE), are implicated in the pathogenesis of Alzheimer's.</p>
<p>Understanding the intricacies of these pathological features is vital for developing targeted therapeutic interventions aimed at halting or slowing the progression of Alzheimer's disease.[6][7][8][9]</p>
<p>Risk Factors:</p>
<p>While age remains the primary risk factor for Alzheimer's disease, recent research has unveiled a multifaceted landscape involving a combination of genetic, environmental, and lifestyle factors.Understanding these elements is crucial for elucidating the complex etiology of Alzheimer's disease and developing effective prevention strategies.[4]</p>
<p>Genetic Factors:</p>
<p>Genetic studies have identified several susceptibility genes associated with Alzheimer's disease, with the apolipoprotein E (APOE) gene being a prominent example.APOE variants, particularly APOE4, are linked to an increased risk of developing Alzheimer's disease.</p>
<p>Ongoing research continues to uncover additional genetic factors that may contribute to an individual's susceptibility.[10]</p>
<p>Environmental Factors:</p>
<p>Environmental factors, including exposure to certain toxins and pollutants, may contribute to the risk of developing Alzheimer's disease.Studies have explored the impact of air pollution, heavy metals, and other environmental stressors on brain health.Understanding these environmental influences is essential for developing strategies to mitigate their effects.[11]</p>
<p>Cardiovascular Health:</p>
<p>Growing evidence suggests a strong connection between cardiovascular health and the risk of</p>
<p>Social and Lifestyle Factors:</p>
<p>Maintaining an active social life and adopting a healthy lifestyle are linked to a lower risk of Alzheimer's disease.Social engagement, regular physical activity, a balanced diet, and adequate sleep contribute to overall brain health.Exploring the intricate interplay of these factors provides a holistic approach to understanding and mitigating Alzheimer's disease risk.</p>
<p>[14]</p>
<p>Cognitive and Physical Activity:</p>
<p>Engaging in mentally stimulating activities and maintaining physical fitness are associated with a lower risk of Alzheimer's disease.Cognitive and physical activities have been proposed as protective factors that enhance neuroplasticity and promote overall brain resilience against age-related cognitive decline.[15] The identification and understanding of diverse risk factors for Alzheimer's disease highlight the complexity of its etiology.Integrating genetic, environmental, and lifestyle factors into a comprehensive risk assessment framework is essential for developing personalized prevention strategies and advancing our ability to mitigate the impact of this devastating neurodegenerative disorder.</p>
<p>Diagnostic Advances:</p>
<p>Recent breakthroughs in neuroimaging and biomarker research have revolutionized Alzheimer's disease diagnosis.Techniques such as positron emission tomography (PET) scans targeting amyloid and tau proteins, along with cerebrospinal fluid analysis, provide valuable insights into disease progression.These diagnostic tools not only enhance early detection but also offer a means to monitor the efficacy of potential therapeutic interventions, fostering a more personalized approach to patient care.[16][17][18]</p>
<p>Therapeutic Approaches:</p>
<p>While current therapeutic strategies focus on symptom management, the quest for diseasemodifying treatments remains ongoing.Anti-amyloid and anti-tau therapies, neuroinflammation modulation, and lifestyle interventions are emerging as promising avenues.</p>
<p>Clinical trials targeting various aspects of the disease process provide hope for future breakthroughs, offering the possibility of not only treating symptoms but also addressing the underlying causes of Alzheimer's disease.[19]</p>
<p>Anti-Amyloid Therapies:</p>
<p>Targeting the amyloid cascade hypothesis, anti-amyloid therapies, such as aducanumab, aim to reduce amyloid-beta plaques.Challenges, including the need for early intervention, are being addressed in ongoing clinical trials.[7,20]</p>
<p>Anti-Tau Therapies:</p>
<p>Focusing on tau protein abnormalities and neurofibrillary tangles, anti-tau therapies are exploring ways to modulate or clear abnormal tau proteins.[21]</p>
<p>Neuroinflammation Modulation:</p>
<p>Recognizing the role of neuroinflammation, therapies are being developed to modulate the inflammatory response and mitigate its impact on neuronal health.[22]</p>
<p>Lifestyle Interventions:</p>
<p>Dietary patterns like the Mediterranean diet, regular exercise, and cognitive training are under investigation as potential preventive and therapeutic measures.[23]</p>
<p>Combination Therapies:</p>
<p>Combining anti-amyloid, anti-tau, and anti-inflammatory agents, along with lifestyle interventions, is being explored for a comprehensive approach to disease modification.[24]</p>
<p>Precision Medicine Approaches:</p>
<p>Precision medicine approaches in Alzheimer's disease (AD) represent a paradigm shift in the diagnosis, treatment, and management of this complex neurodegenerative disorder.These approaches aim to tailor medical care to individual variations in genetics, biomarkers, and other personal factors.One key aspect of precision medicine in AD involves genetic profiling, particularly the identification of specific genetic variants such as the APOE ε4 allele, which can influence an individual's risk of developing the disease.Biomarker-based strategies, including cerebrospinal fluid analyses and neuroimaging, play a crucial role in early detection and monitoring disease progression.The integration of these diverse data points enables clinicians to categorize patients into more precise subgroups, allowing for targeted interventions.Recent advancements in pharmacogenomics further support the development of personalized treatment plans, as they take into account an individual's genetic makeup to optimize therapeutic outcomes.While precision medicine in Alzheimer's disease is still evolving, it holds significant promise in advancing our understanding of disease heterogeneity and providing tailored approaches to diagnosis, treatment, and care.[25][26][27][28] The therapeutic landscape for Alzheimer's disease is evolving with diverse approaches under investigation.Collaborative efforts are crucial to advancing treatments that can transform the management of Alzheimer's disease and improve patients' lives.Currently used therapeutic methods are summed up in Table 1.</p>
<p>3 . 4
34
Alzheimer's disease.Conditions such as hypertension, diabetes, and high cholesterol may contribute to vascular changes that impact brain function.Lifestyle modifications and interventions targeting cardiovascular risk factors are increasingly recognized as potential strategies for Alzheimer's disease prevention.[12] Education and Cognitive Engagement: Higher levels of education and lifelong cognitive engagement have been associated with a reduced risk of Alzheimer's disease.Cognitive reserve, built through education and mental stimulation, may confer resilience against the cognitive decline associated with the disease.Understanding the protective role of cognitive engagement offers valuable insights for preventive interventions.[13]</p>
<p>Table 1 .
1
Currently used therapeutic methods
TherapeuticDescriptionExamplesRefApproachCholnesteraseIncreaseDonepezil,Rivastigmine,[29]inhibitorsacetylocholineGalantaminelevels in brainNMDAReceptorModulate glutamateMemantine[30]AntagonistsactivityAnti-Amyloid AgentsTarget and reduceAducanumab, Solanezumab,[31]beta-amyloidGantenerumabplaquesTau-Targeted Therapies Aim to reduce tauLMTX(Leuco-[32]protein tanglesmethylthioniniumbis(hydromethanesulfonate))Anti-InflamatoryReduceNSAIDs(Non-steroidal[33]Drugsinflammationinanti-inflammatory drugs)brainAntioxidant TherapyCombat oxidativeVitamin E, C, Coenzyme[34]stressQ10Cognitive StimulationEngageandMemory games, puzzles,[35]challenge cognitivecognitive training programsabilitiesPhysical ExercisePromoteoverallAerobic exercise, strength[36]health and braintraining, yogafunctionNutritionalSupport brain healthOmega-3fattyacids,[37]Interventionsthrough dietantioxidants, MediterraneandietMusic and Art Therapy Enhance emotionalListening to music, creating[38]well-beingart
understanding could be enhanced.[42]The results underscored the necessity for targeted educational initiatives to address prevalent misconceptions and to enrich knowledge among the general population.These findings resonate with similar studies conducted in diverse regions, all underscoring the importance of amplifying awareness not only regarding the symptoms and risk factors of Alzheimer's disease but also concerning the available support services for individuals living with Alzheimer's and their caregivers.[43,44]Global campaigns led by organizations like Alzheimer's Disease International (ADI) and national Alzheimer's associations prove crucial in disseminating accurate information, debunking myths, and encouraging proactive engagement with healthcare services.By fostering a more informed and supportive societal environment, these initiatives aim to address the multifaceted challenges associated with Alzheimer's disease.Summary:In wrapping up our exploration of Alzheimer's disease, it becomes evident that while progress has been made, there is much more to uncover about this complex brain condition.As we conclude this overview, it is clear that Alzheimer's research is not a finished story but an ongoing narrative, ever-evolving and adapting to new insights.Collaborative efforts across various disciplines remain paramount in unraveling the mysteries of Alzheimer's disease.It is through these collective endeavors that we will continue to refine our understanding, develop effective preventive strategies, and ultimately pave the way for innovative treatments to alleviate the burden of Alzheimer's on individuals and societies alike.Disclosures: No disclosures.Financial support: No financial support was received.Conflict of interest:The authors declare no conflict of interest.References:1
The global prevalence of dementia: a systematic review and metaanalysis. M Prince, R Bryce, E Albanese, A Wimo, W Ribeiro, C P Ferri, 10.1016/j.jalz.2012.11.007Alzheimers Dement. 912013</p>
<p>Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. R A Sperling, P S Aisen, L A Beckett, 10.1016/j.jalz.2011.03.003Alzheimers Dement. 732011</p>
<p>Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. J C Lambert, Ibrahim - Verbaas, C A Harold, D , 10.1038/ng.2802Nat Genet. 45122013</p>
<p>Alzheimer Disease: An Update on Pathobiology and Treatment Strategies. J M Long, D M Holtzman, 10.1016/j.cell.2019.09.001Cell. 17922019</p>
<p>Alzheimer's disease: the amyloid cascade hypothesis. J A Hardy, G A Higgins, 10.1126/science.1566067Science. 25650541992</p>
<p>The amyloid hypothesis of Alzheimer's disease at 25 years. D J Selkoe, J Hardy, 10.15252/emmm.201606210EMBO Mol Med. 862016 Jun 1</p>
<p>Tau: From research to clinical development. D M Holtzman, M C Carrillo, J A Hendrix, 10.1016/j.jalz.2016.03.018Alzheimers Dement. 12102016</p>
<p>Amyloid plaque core protein in Alzheimer disease and Down syndrome. C L Masters, G Simms, N A Weinman, G Multhaup, B L Mcdonald, K Beyreuther, 10.1073/pnas.82.12.4245Proc Natl Acad Sci U S A. 82121985</p>
<p>The genetics of Alzheimer's disease. L Bertram, R E Tanzi, 10.1016/B978-0-12-385883-2.00008-4Prog Mol Biol Transl Sci. 1072012</p>
<p>Particulate air pollutants, APOE alleles and their contributions to cognitive impairment in older women and to amyloidogenesis in experimental models. M Cacciottolo, X Wang, I Driscoll, 10.1038/tp.2016.280Transl Psychiatry. 712017. 2017 Jan 31</p>
<p>Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the american heart association/american stroke association. P B Gorelick, A Scuteri, S E Black, 10.1161/STR.0b013e3182299496Stroke. 4292011</p>
<p>Cognitive reserve in ageing and Alzheimer's disease. Y Stern, 10.1016/S1474-4422(12)70191-6Lancet Neurol. 11112012</p>
<p>Dementia prevention, intervention, and care. G Livingston, A Sommerlad, V Orgeta, 10.1016/S0140-6736(17)31363-6Lancet. 3902017. 10113</p>
<p>An active and socially integrated lifestyle in late life might protect against dementia. L Fratiglioni, S Paillard-Borg, B Winblad, 10.1016/S1474-4422(04)00767-7Lancet Neurol. 362004</p>
<p>Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria [published correction appears in Lancet Neurol. B Dubois, H H Feldman, C Jacova, 2014 Aug13757</p>
<p>. 10.1016/S1474-4422(14)70090-0Lancet Neurol. 1362014</p>
<p>Toward a biological definition of Alzheimer's disease. Jack CrJr, D A Bennett, K Blennow, 10.1016/j.jalz.2018.02.018Alzheimers Dement. 1442018</p>
<p>Plasma P-tau181 in Alzheimer's disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer's dementia. S Janelidze, N Mattsson, S Palmqvist, 10.1038/s41591-020-0755-1Nat Med. 2632020</p>
<p>Anti-amyloid antibody therapies in Alzheimer's disease. R Perneczky, F Jessen, T Grimmer, 10.1093/brain/awad005Brain. 14632023</p>
<p>Alzheimer's Disease Cooperative Study Data Analysis and Publication Committee. R S Doody, M Farlow, P S Aisen, 10.1056/NEJMc1402193N Engl J Med. 3701514602014Phase 3 trials of solanezumab and bapineuzumab for Alzheimer's disease</p>
<p>Tau: From research to clinical development. D M Holtzman, M C Carrillo, J A Hendrix, 10.1016/j.jalz.2016.03.018Alzheimers Dement. 12102016</p>
<p>Neuroinflammation in Alzheimer's disease. M T Heneka, M J Carson, El Khoury, J , 10.1016/S1474-4422(15)70016-5Lancet Neurol. 1442015</p>
<p>A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. T Ngandu, J Lehtisalo, A Solomon, 10.1016/S0140-6736(15)60461-5Lancet. 38599842015</p>
<p>Trial of Solanezumab for Mild Dementia Due to Alzheimer's Disease. L S Honig, B Vellas, M Woodward, 10.1056/NEJMoa1705971N Engl J Med. 37842018</p>
<p>Alzheimer's disease drug development pipeline: 2020. Alzheimers Dement (N Y). J Cummings, G Lee, A Ritter, M Sabbagh, K Zhong, 10.1002/trc2.120502020. 2020 Jul 166e12050Published</p>
<p>A precision medicine initiative for Alzheimer's disease: the road ahead to biomarker-guided integrative disease modeling. H Hampel, S E O'bryant, S Durrleman, E Younesi, Climacteric. 2152018</p>
<p>Novel Alzheimer disease risk loci and pathways in African American individuals using the African Genome Resources panel: a meta-analysis. B W Kunkle, M Schmidt, H U Klein, A C Naj, Hamilton-Nelson, JAMA neurology. 7642019</p>
<p>Clinical implementation of integrated genomic profiling in individuals with Alzheimer's and other neurodegenerative diseases. J S Goldman, S E Hahn, Molecular Case Studies. 2612972016</p>
<p>Donepezil for dementia due to Alzheimer's disease. J Birks, R J Harvey, 10.1002/14651858.CD001190.pub2Cochrane Database Syst Rev. D0011902006. 2006 Jan 25Published</p>
<p>Memantine in moderate-to-severe Alzheimer's disease. B Reisberg, R Doody, A Stöffler, 10.1056/NEJMoa013128N Engl J Med. 348142003</p>
<p>Alzheimer's disease. P Scheltens, K Blennow, M M Breteler, 10.1016/S0140-6736(15)01124-1Lancet. 3882016. 10043</p>
<p>Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial. S Gauthier, H H Feldman, L S Schneider, 10.1016/S0140-6736(16)31275-2Lancet. 3882016. 10062</p>
<p>Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. P S Aisen, K A Schafer, M Grundman, 10.1001/jama.289.21.2819JAMA. 289212003</p>
<p>Vitamin E and donepezil for the treatment of mild cognitive impairment. R C Petersen, R G Thomas, M Grundman, 10.1056/NEJMoa050151N Engl J Med. 352232005</p>
<p>Cognitive training in Alzheimer's disease: a meta-analysis of the literature. D I Sitzer, E W Twamley, D V Jeste, 10.1111/j.1600-0447.2006.00789.xActa Psychiatr Scand. 11422006</p>
<p>Effect of physical activity on cognitive function in older adults at risk for Alzheimer disease: a randomized trial. N T Lautenschlager, K L Cox, L Flicker, 2009 Jan 21301276published correction appears in JAMA</p>
<p>. 10.1001/jama.300.9.1027JAMA. 30092008</p>
<p>Fat intake at midlife and cognitive impairment later in life: a population-based CAIDE study. M H Eskelinen, T Ngandu, E L Helkala, 10.1002/gps.1969Int J Geriatr Psychiatry. 2372008</p>
<p>Cognitive, emotional, and social benefits of regular musical activities in early dementia: randomized controlled study. T Särkämö, M Tervaniemi, S Laitinen, 10.1093/geront/gnt100Gerontologist. 5442014</p>
<p>Effects of the home environmental skill-building program on the caregiver-care recipient dyad: 6-month outcomes from the Philadelphia REACH Initiative. L N Gitlin, L Winter, M Corcoran, M P Dennis, S Schinfeld, W W Hauck, 10.1093/geront/43.4.532Gerontologist. 4342003</p>
<p>Family caregivers of people with dementia. H Brodaty, M Donkin, 10.31887/DCNS.2009.11.2/hbrodatyDialogues Clin Neurosci. 1122009</p>
<p>Pharmacogenomics in Alzheimer's disease. R Cacabelos, 10.1007/978-1-59745-205-2_10209Methods Mol Biol. 4482008</p>
<p>Public Knowledge about Dementia in Poland-A Survey Study. A Skowronek, K Bojkowska-Otrębska, B Łabuz-Roszak, 10.3390/jcm12247675Journal of Clinical Medicine. 122476752023</p>
<p>Public Awareness of Alzheimer's Disease: A Cross-Sectional Study from Saudi Arabia. N M Alorfi, 10.2147/IJGM.S37344736199585PMC9527696Int J Gen Med. 152022 Sep 28</p>
<p>Public Awareness, Knowledge, and Attitude Toward Alzheimer's Disease in Makkah, Saudi Arabia. Cureus. J Muglan, R M Alkhaldi, M M Alsharif, S I Almuwallad, R S Alotaibi, 10.7759/cureus.4904738116357PMC107285722023 Nov 1915e49047</p>            </div>
        </div>

    </div>
</body>
</html>